Drugs / SHR-9839
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05836948 | May 2023 → May 2026 overdue | neoplastic disease or syndrome | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07229638 | Feb 2026 → Apr 2027 expected | cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06385678 | Jul 2024 → Dec 2025 overdue | — | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06474455 | Jul 2024 → Jun 2029 expected | cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07751341 | Sep 2026 → Dec 2027 expected | esophageal squamous cell carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06915142 | Apr 2025 → Dec 2026 expected | cancer | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT06703177 Background | Feb 2025 → Jan 2026 overdue | cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06754930 Background | Feb 2025 → Dec 2027 expected | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-9839 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06385678 ↗ |
| Route | Subcutaneous | “SHR-9839 for Injection (sc)” NCT06474455 ↗ |